Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Artfinder is the art world's first certified B corporation that is on a mission to create a world where art benefits everyone. Operating in the $55 billion+ wall décor and online art market, the company is backed by Wellington Partners, and private investors in the UK, US and Switzerland. It has 60,000 customers, 6,000 artists and a collection of 470,000 artworks. The company believes in establishing direct contact with artists to select or commission work and negotiate prices. Customers have rated the company highly with 4.8+ Trustpilot reviews. The company will use the investment to supercharge its growth, grow its team and improve its platform.
days to go:
Expired
investment:
£834,056
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.
days to go:
Expired
investment:
£522,689
QFinds is a purpose-built hiring tool that enables employers to easily and efficiently pre-screen candidates, conduct interviews and generate employment contracts. The company asserts that it is a UK government vetted 'Kickstart Scheme' representative and can get small businesses grants to hire interns having already processed over 100 job applications. QFinds claims that its app has been downloaded 2 million+ times garnering 24,000 reviews averaging 4.8/5 stars. QFinds also points out that bad hirings cost the UK up to £6.7 billion in turnover, productivity, and training. It seeks to change this and disrupt the £39 billion recruitment market. The company has partnered with notable entities like University College London, Kings College London and Brunel University London, intending to use them as strategic partners to increase job seekers signing up to and using its app. QFinds will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£222,866
Customers can receive free parking at an airport by simply allowing others to rent out their vehicles, instead of leaving their cars idle in the airport cark park. ForestCar aim to help reduce harmful vehicle emission and are a part of a reforestation programme whereby a share of their revenue is invested in restoring global rainforests.
days to go:
Expired
investment:
£210,000
Urban is a wellness app that allows customers to book massages, beauty treatments, personal training and more at the customer's doorstep in 60 minutes. The company's practitioners are already operating in London, Paris, Manchester and Birmingham covering all aspects of wellness, from massage to mindfulness and beyond. Urban has delivered over 650,000 appointments till date, witnessed £43 million in cumulative sales value since August 2018, onboarded 3,800 partner practitioners, and saw 7,300+ reviews on Apple app store with an average rating of 4.8/5 stars. It will use the investment to drive towards Operating Expense (OpEx) profitability by the end of Q1 2021, reach EBITDA positive by the end of 2021, and scale into new markets through remote expansion.
days to go:
Expired
investment:
£5,877,517
